• 1
    Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362.
  • 2
    Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 186-189.
  • 3
    Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
  • 4
    Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
  • 5
    Jacobson IM, McHutchison JG, Dusheiko GM, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
  • 6
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
  • 7
    Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012; 32: 88-102.
  • 8
    White PW, Llinàs-Brunet M, Amad M, Bethell RC, Bolger G, Cordingley MG, et al. Preclinical characterization of non covalent HCV NS3/4A protease inhibitor BI 201335 [Abstract 777]. J Hepatol 2010; 52( Suppl 1): S302.
  • 9
    Yong C-L, Scherer J, Sabo J, Stern JO, Steinmann G, Böcher W. BI 201335 pharmacokinetics and early effect on viral load in HCV genotype-1 patients [Abstract 1249]. J Hepatol 2011; 54( Suppl 1): S493.
  • 10
    Manns MP, Bourlière M, Benhamou Y, Pol S, Bonacini M, Trepo C, et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 2011; 54: 1114-1122.
  • 11
    Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One 2009; 4: e8209.
  • 12
    Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Müh U, Welker M, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767-1777.
  • 13
    Sulkowski MS, Bourlière M, Bronowicki J-P, Streinu-Cercel A, Preotescu L, Asselah T, et al. SILEN-C2: sustained virologic response (SVR) and safety of BI 201335 combined with peginterferon alfa-2a and ribavirin (P/R) in chronic HCV genotype-1 patients with non-response to P/R [Abstract 66]. J Hepatol 2011; 54( Suppl 1): S30.
  • 14
    Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomized, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 1467-1475.
  • 15
    Kukolj G, Benhamou Y, Manns MP, Bourlière M, Pol S, Schuchmann M, et al. BI 201355, a potent HCV NS3 protease inhibitor, in treatment-naïve and -experienced chronic HCV genotype-1 infection: genotypic and phenotypic analysis of the NS3 protease domain [Abstract 954]. J Hepatol 2009; 50( Suppl 1): S347.
  • 16
    Sane R, Podila L, Mathur A, Mease K, Taub M, Huang Q, et al. Mechanisms of isolated unconjugated hyperbilirubinaemia induced by the HCV NS3/4A protease inhibitor BI 201335 [Abstract 1236]. J Hepatol 2011; 54( Suppl 1): S488.
  • 17
    Huisman MT, Snoeys J, Monbaliu J, Martens M, Sekar V, Raoof A. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters [Abstract 278]. HEPATOLOGY 2010; 52( Suppl 1): S461A.
  • 18
    Sulkowski MS. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis 2003; 23: 183-194.
  • 19
    Pol S, Berg T, Bonacini M, Schuchmann M, Lalezari J, Erhardt A, et al. SVR and pharmacokinetics of the HCV protease inhibitor BI201335 with PegIFN/RBV in HCV genotype-1 patients with compensated liver cirrhosis and non-response to previous PegIFN/RBV [Abstract 1231]. J Hepatol 2011; 54( Suppl 1): S486.
  • 20
    Dieterich D, Asselah T, Guyader D, Berg T, Ceausu E, Preotescu L, et al. SILEN-C3: treatment for 12 or 24 weeks with BI 201335 combined with peginterferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype-1 HCV infection [Abstract 36]. HEPATOLOGY 2011; 54( Suppl): S378A.